Differences between myeloperoxidase‑antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3‑ANCA associated vasculitis: A retrospective study from a single center in China

Wu,Ting; Shen,Chanjuan; Zhong,Yong; Ooi,Joshua D.; Zhou,Ya-Ou; Chen,Jin-Biao; Meng,Ting; Xiao,Zhou; Lin,Wei; Ao,Xiang; Xiao,Xiangcheng; Zhou,Qiaoling; Xiao,Ping

doi:10.3892/etm.2021.9993

Differences between myeloperoxidase‑antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3‑ANCA associated vasculitis: A retrospective study from a single center in China

Authors:
- Ting Wu
- Chanjuan Shen
- Yong Zhong
- Joshua D. Ooi
- Ya-Ou Zhou
- Jin-Biao Chen
- Ting Meng
- Zhou Xiao
- Wei Lin
- Xiang Ao
- Xiangcheng Xiao
- Qiaoling Zhou
- Ping Xiao
View Affiliations

Affiliations: Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Hematology, the Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, P.R. China, Department of medicine, Centre for Inflammatory Diseases, Monash Medical Centre, Monash University, Clayton, Victoria 3168, Australia, Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Medical Records and Information, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 26, 2021 https://doi.org/10.3892/etm.2021.9993
Article Number: 561
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In antineutrophil cytoplasmic autoantibody (ANCA)‑associated vasculitides (AAV), the two major target antigens of ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO). Evidence is accumulating that there are distinct differences between patients with PR3‑AAV and those with MPO‑AAV. In the present study, the clinicopathological features and prognosis of patients with PR3‑AAV and MPO‑AAV from a single center in China were retrospectively analyzed. A total of 212 Chinese patients with AAV were recruited in the present study; 189/212 (89.15%) patients were classified as having MPO‑AAV and 23/212 (10.85%) patients as having PR3‑AAV. Compared with those in the PR3‑AAV group, patients in the MPO‑AAV group were older and less frequently had ear, nose and throat or ophthalmic involvement. MPO‑AAV patients had higher levels of serum creatinine and proteinuria at baseline. No significant difference was observed with regard to the pathological changes of the glomeruli and tubulointerstitium between the two groups. The probability of developing end‑stage renal disease was significantly higher in patients with MPO‑AAV compared with that in patients with PR3‑AAV. There was no significant difference in the one‑year patient survival rate between the two groups. However, differences in certain clinical characteristics and outcomes were observed between MPO‑AAV and PR3‑AAV patients. A large national investigation of AAV is required to confirm the concept that PR3‑AAV and MPO‑AAV are distinct disease entities.

View Figures

View References

1	Falk RJ and Jennette JC: ANCA small-vessel vasculitis. J Am Soc Nephrol. 8:314–322. 1997.PubMed/NCBI
2	Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al: The American college of rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 33:1135–1136. 1990.PubMed/NCBI View Article : Google Scholar
3	Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, et al: 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65:1–11. 2013.PubMed/NCBI View Article : Google Scholar
4	Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, et al: Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 367:214–223. 2012.PubMed/NCBI View Article : Google Scholar
5	Hilhorst M, van Paassen P and Tervaert JW: Limburg Renal Registry. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 26:2314–2327. 2015.PubMed/NCBI View Article : Google Scholar
6	Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, et al: Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 68:1700–1710. 2016.PubMed/NCBI View Article : Google Scholar
7	Deshayes S, Martin Silva N, Khoy K, Yameogo S, Mariotte D, Lobbedez T and Aouba A: Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford). 58:1731–1739. 2019.PubMed/NCBI View Article : Google Scholar
8	Hong Y, Shi P, Liu X, Yang L, Li K, Xu F, Liang S, Liu Z, Zhang H, Chen Y and Hu W: Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: A retrospective single-center study. Clin Rheumatol. 38:1665–1673. 2019.PubMed/NCBI View Article : Google Scholar
9	Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, et al: Modification and validation of the birmingham vasculitis activity score (version 3). Ann Rheum Dis. 68:1827–1832. 2009.PubMed/NCBI View Article : Google Scholar
10	Chen M, Xing GQ, Yu F, Liu G and Zhao MH: Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant. 24:1247–1252. 2009.PubMed/NCBI View Article : Google Scholar
11	Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, et al: Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 21:1628–1636. 2010.PubMed/NCBI View Article : Google Scholar
12	Chen YX, Xu J, Pan XX, Shen PY, Li X, Ren H, Chen XN, Ni LY, Zhang W and Chen N: Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: A study of 186 patients and metaanalysis. J Rheumatol. 44:304–313. 2017.PubMed/NCBI View Article : Google Scholar
13	Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, et al: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 75:1583–1594. 2016.PubMed/NCBI View Article : Google Scholar
14	Huang L, Zhong Y, Ooi JD, Zhou YO, Zuo X, Luo H, Chen JB, Wu T, Yang Y, Meng T, et al: The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis. Int Immunopharmacol. 76(105883)2019.PubMed/NCBI View Article : Google Scholar
15	Watts RA, Mooney J, Skinner J, Scott DG and Macgregor AJ: The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology (Oxford). 51:926–931. 2012.PubMed/NCBI View Article : Google Scholar
16	Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, Matsuo S, Ozaki S, Endo T, Muso E, et al: Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 41:325–333. 2014.PubMed/NCBI View Article : Google Scholar
17	Furuta S, Chaudhry AN, Arimura Y, Dobashi H, Fujimoto S, Homma S, Rasmussen N and Jayne DR: Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts. J Rheumatol. 44:216–222. 2017.PubMed/NCBI View Article : Google Scholar
18	Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, Garcia-Porrua C and Bentham GA: Epidemiology of vasculitis in Europe. Ann Rheum Dis. 60:1156–1157. 2001.PubMed/NCBI View Article : Google Scholar
19	Liu LJ, Chen M, Yu F, Zhao MH and Wang HY: Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford). 47:708–712. 2008.PubMed/NCBI View Article : Google Scholar
20	Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, Yin H, Chen J, Pu J, Peng Z, et al: Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 18:3984–3990. 2019.PubMed/NCBI View Article : Google Scholar
21	Scott J, Hartnett J, Mockler D and Little MA: Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review. Autoimmun Rev. 19(102660)2020.PubMed/NCBI View Article : Google Scholar
22	Chang DY, Li ZY, Chen M and Zhao MH: Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. Semin Arthritis Rheum. 48:701–706. 2019.PubMed/NCBI View Article : Google Scholar
23	Pearce FA, Craven A, Merkel PA, Luqmani RA and Watts RA: Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 56:1962–1969. 2017.PubMed/NCBI View Article : Google Scholar
24	Ponte C, Agueda AF and Luqmani RA: Clinical features and structured clinical evaluation of vasculitis. Best Pract Res Clin Rheumatol. 32:31–51. 2018.PubMed/NCBI View Article : Google Scholar
25	Franssen C, Gans R, Kallenberg C, Hageluken C and Hoorntje S: Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med. 244:209–216. 1998.PubMed/NCBI View Article : Google Scholar
26	Falk RJ, Hogan S, Carey TS and Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The glomerular disease collaborative network. Ann Intern Med. 113:656–663. 1990.PubMed/NCBI View Article : Google Scholar
27	Homma S, Suzuki A and Sato K: Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol. 17:667–671. 2013.PubMed/NCBI View Article : Google Scholar
28	Franssen CF, Gans RO, Arends B, Hageluken C, ter Wee PM, Gerlag PG and Hoorntje SJ: Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int. 47:193–199. 1995.PubMed/NCBI View Article : Google Scholar
29	Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P and Cohen Tervaert JW: ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 26:537–542. 2015.PubMed/NCBI View Article : Google Scholar
30	Sinico RA, Radice A, Corace C, DI Toma L and Sabadini E: Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis. Ann N Y Acad Sci. 1050:185–192. 2005.PubMed/NCBI View Article : Google Scholar
31	Liu Y, Zhang Y, Liu D, Tan X, Tang X, Zhang F, Xia M, Chen G, He L, Zhou L, et al: Prediction of ESRD in IgA nephropathy patients from an Asian cohort: A random forest model. Kidney Blood Press Res. 43:1852–1864. 2018.PubMed/NCBI View Article : Google Scholar
32	Li D, Zou L, Feng Y, Xu G, Gong Y, Zhao G, Ouyang W, Thurman JM and Chao W: Complement factor B production in renal tubular cells and its role in sodium transporter expression during polymicrobial sepsis. Crit Care Med. 44:e289–e299. 2016.PubMed/NCBI View Article : Google Scholar
33	Xiao H, Schreiber A, Heeringa P, Falk RJ and Jennette JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 170:52–64. 2007.PubMed/NCBI View Article : Google Scholar
34	Fukui S, Iwamoto N, Takatani A, Igawa T, Shimizu T, Umeda M, Nishino A, Koga T, Kawashiri SY, Tamai M, et al: Antineutrophilic cytoplasmic antibody-associated vasculitis with and without renal involvement: C3 contributes to prognosis, but renal involvement does not. Int J Rheum Dis. 22:789–796. 2019.PubMed/NCBI View Article : Google Scholar
35	Choi H, Kim Y, Jung SM, Song JJ, Park YB and Lee SW: Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. Clin Exp Nephrol. 23:223–230. 2019.PubMed/NCBI View Article : Google Scholar
36	Liu H, Peng Y, Liu H, Liu Y, Yuan S, Liu F, Yang D, Chen X, He L, Fu M, et al: Renal biopsy findings of patients presenting with isolated hematuria: Disease associations. Am J Nephrol. 36:377–385. 2012.PubMed/NCBI View Article : Google Scholar
37	Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA and Hagen EC: European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 61:80–89. 2002.PubMed/NCBI View Article : Google Scholar
38	Cordova-Sanchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO and Correa-Rotter R: Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol. 35:1805–1816. 2016.PubMed/NCBI View Article : Google Scholar
39	Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J and Tesar V: Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res. 28:144–152. 2005.PubMed/NCBI View Article : Google Scholar
40	Mohammad AJ and Segelmark M: A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 41:1366–1373. 2014.PubMed/NCBI View Article : Google Scholar
41	de Joode AA, Sanders JS and Stegeman CA: Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 8:1709–1717. 2013.PubMed/NCBI View Article : Google Scholar
42	Ma Y, Han F, Chen L, Wang H, Han H, Yu B, Xu Y and Chen J: The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: A retrospective study. BMC Nephrol. 18(381)2017.PubMed/NCBI View Article : Google Scholar
43	Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA and Hagen EC: European Vasculitis Study Group (EUVAS). Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 62:1732–1742. 2002.PubMed/NCBI View Article : Google Scholar